Radiation Oncology
First, a brief comment: with the imminent release of this Integrative Tumor Board case to the panel, a query was made as to whether there would be any response from Radiation Oncology given that the topic was ovarian cancer. My response was an immediate "yes," since (1) in the modern era, the best programs of integrative oncologic care are derived through multidisciplinary management; (2) regardless of the small therapeutic role that radiation oncology may actually play in this particular woman's care, our impressions as oncologists are useful and allow another perspective that may differ from that of surgical and medical oncology disciplines; and (3) the possibility of a patient with virtually any oncologic condition to undergo a radiation oncology consultation is not only valuable in its own right but may also in the long run improve patient compliance with the final treatment program outlined. By demonstrating a quest for unbiased and holistic evaluations from all disciplines through the multidisciplinary tumor board setting, this activity can instill in patients a more fervent appreciation and confidence that all clinical possibilities have been explored and a consensus reached. Finally, (4) in specific instances, radiation therapy can provide a treatment alternative in the comprehensive treatment program for individual patients. The patient's initial presentation and management would appear to reflect the prevailing standard of care, certainly in the United States. The tumor burden that would likely remain after definitive surgery would be minimally confined to the whole abdomen, given both the stage II local disease outside the ovary and the extensiveness of the fluid cytologies. I would only observe that outside of the United States, the use of external beam radiation therapy, typically with whole abdominal radiation therapy (WART) with a pelvic boost, has been a viable option for many patients in the pTNM stage I-IA-C category with low-grade tumors, with acceptable morbidities and comparable local control and survival 1 when compared to both historical controls and patients treated with a combination of both chemotherapy and radiation. With highenergy linear accelerators, reasonable fractionation schedules, CT-based dosimetric planning, and enhanced management of toxicities, treatment tolerances have improved versus the previous historical use of "moving strip" abdominal therapy on Co-60 units from the 1960s. Yet, acute toxicities and especially the impact on bone marrow reserves have traditionally been stated as the most limiting in practical management. In light of cytotoxic chemotherapy programs that can extend coverage beyond the abdominopelvic confines, this latter approach has been favored. Russell 2 and Chao et al 3 reviewed the international literature that speaks to radiation's historical role in ovarian cancer management. It is hoped that the increasing use of radioprotectors such as amifostene may become integrated into treatment protocols for gynecologic malignancies using ionizing radiation, which will further improve the benefit/risk ratio in this anatomical region.
The apparent recurrence will need to be analyzed from several perspectives, not the least of which is proper delineation of the area(s) of residual, recurrent, or progressive disease. Given the time frame of 14 months since completing chemotherapy (and, hence, approximately 16 months since diagnosis), this CT-diagnosed disease and rise in CA-125 could possibly reflect the incomplete destruction of this lingering group of tumor clones surviving chemotherapy. This subset of tumor clones is inferred by a much faster doubling time, as seen in the rapid rise in CA-125. To best define region(s) of tumor persistence and routes of potential locoregional spread along lymphatic, intraperitoneal, or hematogenous routes, both radiation and surgical perspectives should note which side contained the enlarged pelvic node; the right side would be a reasonable assumption given the original disease location. The biopsies of the bladder and rectal serosa were not identified as to side versus central location, which would improve speculation as to route(s) of spread. We usually ask that oncologic surgeons, when encountering "gross" disease that is resected, leave identifying titanium clips (or comparable markers) should that area need to be identified at some later date as requiring localized treatment.
Another interesting aspect of this recurrence is the CA-125 value of 91, whereas the original CA-125 at the time of a 19 cm serous papillary cystadenocarcinoma with biopsy-positive pelvic disease and washings was only 145 U/mL. There appears to be some discrepancy between original and current volumes and respective values of CA-125, and further clarification of the true correlation with tumor burden, preferably through noninvasive means, could be useful in charting treatment strategy. If the imaging studies only identify a solitary 2-cm node on CT, then one may speculate that (1) from perhaps an initial heterogeneous tumor burden now emerges a subpopulation of metastatic disease having a greater correlation with CA-125, (2) there is more disease than imaging has disclosed, or (3) the original tumor simply did not produce much CA-125 for its volume. In the evaluation, one should include a pelvic exam to exclude a cul-desac mass, or worrisome findings despite CT imaging. A complete metabolic profile to screen for either renal, hepatic, or bone abnormalities would, moreover, be intuitively obvious, as would a screening urinalysis. A CT of the chest, and if clinically warranted a radionuclide bone scan, can be pursued. Perhaps these can be all encompassed through a fluorescent positron emission tomography (PET) scan (see below).
One must acknowledge the reported limited impact on overall survival for repeat surgical staging and debulking when recurrent disease burden is small, given the increased risks inherent to repeat surgery. Moreover, because the standard management may not be fundamentally changed (ie, systemic chemotherapy, although the delivery system may include intravenous and/or intraperitoneal routes), one may argue against it. However, there may be other reasons to clearly identify disease burden before treatment, especially if it appears to be localized versus extensive. These would be (1) more directed surgical attention if restaging and debulking is elected and (2) the potential use of "consolidative" radiation therapy to limited areas of bulk disease at some later date. Although controversial, extrapolation from other tumor systems including both epithelial and lymph would support the notion of increased local control, with or without attendant favorable change in survival when radiation is used later in this adjuvant fashion or if incomplete response to second line therapy is realized. Radiation presents another non-cross-reacting route for tumor control, although in this patient's case its use would be restricted to the scenario of isolated local pelvic disease without intra-abdominal spread where persistent tumor cell infestation would be harbored. In the latter case of incomplete response, more targeted therapies could be arranged through properly focused radiation portals.
In any event, further staging might best be performed in 2002 through PET scanning, especially in an image fusion mode with either CT or magnetic resonance imaging. 4 This study should correlate the known disease with heightened biologic uptake of glucose at minimum. It should, however, improve identification of smaller (under 1 cm nodal or implant) disease pockets, which can then either guide the surgeon to resection if clinically warranted, be used to serially monitor response from cancer-directed therapy, or provide target correlation if locoregional radiation therapy were to be offered in a consolidative fashion. Other radioimaging techniques using monoclonal antibodies such as anti-CEA, OncoScint ® , and so on would seem to have become less valuable, although recent research using 3 different monoclonal antibodies, including HMFG1, OC-125, and H17E2 labeled with In-111 or I-123 reported localization of ovarian cancer in more than 80% of instances. 5 From a broader holistic perspective, the main issues to address for this patient are oncologic, general medical and nutritional, and social and psychospiritual. Any notion of a recurrence, especially so soon after rather vigorous primary treatment, can have a rather pronounced negative emotional impact that must be addressed and not ignored. The patient's underlying body habitus, age, and other social circumstances will require appropriate attention to maximize potential outcomes and compliance with the holistic management regimen. Social services, psychological counseling, and other avenues to reduce the "stress" inherent in this situation will only go to furthering both her tolerance, coping skills, and possibilities for a favorable retreatment strategy. The recognition that her overall prognosis would be best termed guarded, since only a subset go on to durable disease-free survival, will loom in the background. Her younger age, lack of relationship support (ie, unmarried, only 1 brother, outside homeland), cultural interpretations of illness, and the stress and responsibility apparent in her workplace are potent forces that can clearly affect outcome.
Regardless of the use of surgical debulking and second staging procedure, the patient will likely undergo intensive cytotoxic therapy once again. If limited disease is found at surgery and if cytotoxic therapy results in both serologic and imaging complete response, the options at that point would be observation versus further therapy, enrollment in clinical trial for adjuvant therapies perhaps including biologicals, or perhaps treatment with radiation therapy to reduce the likelihood of local recurrence. If she does not respond completely to this regimen and a tumor burden site(s) can be identified via imaging, then local radiation therapy can provide an option to at least reduce the progression of disease and with it, the morbidity of cancer infiltration in these pelvic organs. For patients with poor prognosis, both in ovarian cancer reviews and in a more recent report by MacGibbon et al, 6 use of WART as salvage or consolidation therapy assisted only a selected subgroup of patients; WART had overall acceptable toxicity but no clear-cut overall survival advantage. Individualized therapy would appear to be the key, weighing the improvement in local failure or freedom from progression with morbidity profile, which escalates with each course of therapy.
Parenthetically, it should be remembered that radiation therapy, although not the main focus for active management in the curative setting, remains both a viable option and active contributor to the palliation of various symptomatic presentations of ovarian cancer such as local obstructions, bleeding, bone pain from metastases, and so on. Moreover, although rarely used in modern circles, radioactive P-32 instilled intraperitoneally has a historical track record of reducing symptomatic ascites, although it has serious limitations if adhesions and the lack of "free flow" of fluids in the abdomen is documented, or if prior external beam radiation has been used.
Perhaps the future may hold better promise for CA-125-related radioimmunotherapy as a viable option that could combine the efficacy of monoclonal antibody-targeted cell therapy with radiation therapy delivered at the cellular level to further eradicate disease. Similar comments hold for gene-based therapeutics.
